Overall verdict
Neutral
6.2/10
1-year performance
+258.47%
Score breakdown
Up 258.5% over 1 year, 32% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
7 analysts.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Jodie Morrison
Founded
2015
Employees
24
Revenue / employee
2.2M USD
Next earnings
March 10, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC0.81%
- Bank of New York Mellon Corp0.04%
- FMR LLC0.01%
- Rest of the register99.14%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
23.57 USD
52-week low
1.91 USD
1-year performance
258.47%
Rising
Year-to-date performance
169.39%
Rising
Drawdown
-62.28%
Major drawdown
Position in the 52-week range
32% of range
Gross margin 99.4%, net margin 60.0%, ROIC 22.7%, ROE 24.0%.
Net margin
60.02%
Exceptional
Sector -208.32%|S&P 13.40%
Gross margin
99.35%
Exceptional
Return on equity (ROE)
23.96%
High
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
22.74%
High
Free cash flow margin (FCF)
-37.34%
Negative
Profit-to-cash conversion (FCF conversion)
-0.62x
Low
Revenue to net income
Growth
10.0/1081.9% a year over 5.
Revenue (trailing 12 months)
53.7M USD
Revenue growth (1y)
—
Revenue growth (3y)
1575.09%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
3.3/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
2.7x
Cheap
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
0.05
Growth unpriced
Sector -0.08|S&P 0.91
P/E vs its own 5-year history
among the 33% highest valuations
Pricier than usual
Market cap
266M USD
Financial strength
9.8/10Cash covers 5653.8% of the debt, net debt/EBITDA -1.9x.
Net debt / EBITDA
-1.9x
Net cash
Gearing (net debt / equity)
-98.89%
Net cash
Cash
290M USD
Cash / market cap
108.86%
Very solid
Cash / total debt
5653.79%
Net cash
Interest coverage
15.4x
Very solid
Net debt
-284M USD
Equity
288M USD
Closed daily candles, 2 years
Last close on November 11, 2026: 9.20 USD
- MM208.71
- MM509.39
- MM2009.44
- RSI 1452.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+5.99%
200-day average slope, 3 months
+34.37%
50-day average slope, 1 month
-23.89%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.27 % per day
Volatility change
-65.07%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.40 (7) | -1.13 (1) | 0 (6) | -39 (2) | -35 (6) |
| 2027 | -2.16 (7) | -1.02 (1) | 1 (6) | -70 (2) | -80 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 5, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FIXX | 6.2 | 6.0 | 266M USD | 2.7x | 60.0 % | — | 22.7 % | -1.9x | -7.5 % | 258.5 % | ||
| 2 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 3 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 4 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 5 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 6 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
